六分鐘行走測試(6-minute walking test)於臨床上運用,已被證明為有效及可靠的評估心、肺等疾病病人運動耐力之方法。同時,臨床上重複測量六分鐘行走測試之變化,可做為監測病人疾病嚴重度,及判斷介入措施後改變之成效。因此,為使六分鐘行走測試成為評估運動耐力與介入措施成效的客觀指標,其量化數值的界定為目前各科專家所努力研究的方向。但直至目前為止,六分鐘行走測試於各專科用的臨床最小重要差異值(minimal clinicallyimportant difference, MCID),仍存在爭議。因有鑑於六分鐘行走測試對於慢性阻塞性肺病病人臨床使用的重要,故本文將近年來所發表實證文獻,做綜整性的討論。冀望此探討結果,得以提供臨床醫護人員或研究者進行以六分鐘行走測試作為疾病嚴重度及介入成效評值的參考依據。
This article critically reviews evidence based on the value of 6MWT and it’s MCID used in patients diagnosed with chronic obstructive pulmonary disease (COPD). Measurements of the 6MWT can be used to detect clinical relevant disease progression and the effectiveness of interventions. Health care experts recommended the 6MWT as an objective tool and worthy of investment to examine its cut-point value for clinical guidance. However, the minimal clinically important difference (MCID) of 6MWT used to monitor the disease progression or to evaluate the outcomes is still under discussion. The goal is to provide recommendations on clinical application and research for the use of 6MWT in patients with COPD to monitor disease progression and effectiveness of interventions. The 6-minute walk test (6MWT) is considered to be a valid and reliable assessment tool for exercise tolerance in patients with cardiac or pulmonary diseases.